C8788

Complement C3 deficient serum human

substrate serum for C3 activity

• NACRES: NA.32
• UNSPSC Code: 12352200
• Biological source: human
• Form: solution
• Shipped in: dry ice

Properties

• biological source: human
• Quality Segment: 200
• form: solution
• usage: substrate serum for C3 activity
• technique(s): activity assay: suitable
• impurities: infectious agent, tested
• UniProt accession no.: P01024
• shipped in: dry ice
• storage temp.: −70°C
• Gene Information: human ... C3(718)

Description

General description

Complement C3 deficient serum is a normal human serum in which C3 protein is removed by affinity chromatography. Depleted serum helps in the complement cascade up to the preferred convertase level. It eases the formation of enzyme complex from purified components.

Application

Complement C3 deficient serum human has been used:

• as a component of the culture medium to study the influence of the inhibition of complement activation on complement receptors (CR3 and C3aR) expression in CD3+CD56+NKT-like cells
• as a negative control to evaluate the downstream complement activation post-mannan-binding lectin (MBL) pathway activation
• to study the opsonization of foreign particles by complement system

Physical form

Supplied as a solution in phosphate buffered saline, pH 7.4

Analysis Note

C3 is depleted by immunoadsorption as judged by a highly sensitive hemolytic assay.

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Safety Information

• Storage Class: 10 - Combustible liquids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable